SG Americas Securities LLC Has $28.58 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

SG Americas Securities LLC lifted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 13.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,044 shares of the medical instruments supplier’s stock after purchasing an additional 13,135 shares during the period. SG Americas Securities LLC’s holdings in West Pharmaceutical Services were worth $28,584,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Holocene Advisors LP acquired a new position in shares of West Pharmaceutical Services during the 3rd quarter valued at $49,085,000. Nordea Investment Management AB grew its holdings in West Pharmaceutical Services by 42.7% in the fourth quarter. Nordea Investment Management AB now owns 14,950 shares of the medical instruments supplier’s stock worth $4,122,000 after purchasing an additional 4,477 shares during the period. JPMorgan Chase & Co. grew its holdings in West Pharmaceutical Services by 7.7% in the third quarter. JPMorgan Chase & Co. now owns 236,963 shares of the medical instruments supplier’s stock worth $62,163,000 after purchasing an additional 16,919 shares during the period. Birch Hill Investment Advisors LLC increased its stake in West Pharmaceutical Services by 11.5% in the fourth quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock valued at $41,862,000 after purchasing an additional 15,678 shares in the last quarter. Finally, Brendel Financial Advisors LLC bought a new stake in West Pharmaceutical Services in the fourth quarter valued at $3,742,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on WST. Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Weiss Ratings raised West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Morgan Stanley raised their price objective on West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a research note on Friday, May 29th. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Finally, Stephens reiterated an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $340.09.

West Pharmaceutical Services Trading Up 1.9%

NYSE:WST opened at $336.09 on Wednesday. West Pharmaceutical Services, Inc. has a 52 week low of $206.80 and a 52 week high of $336.82. The firm has a 50-day moving average price of $308.92 and a two-hundred day moving average price of $274.16. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The firm has a market cap of $23.74 billion, a price-to-earnings ratio of 44.93, a price-to-earnings-growth ratio of 2.76 and a beta of 1.18.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The firm had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.67 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The company’s revenue was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities analysts expect that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.

Insider Buying and Selling at West Pharmaceutical Services

In other news, VP Annette F. Favorite sold 2,817 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This trade represents a 14.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares in the company, valued at $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is currently owned by insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.